Hormone – Talk Bio

Novo Nordisk and Septerna Forge $2.2B+ Collaboration on Oral Obesity and Diabetes Drugs

3 weeks ago talkbio0Tagged cardiometabolic diseases, Collaboration, Diabetes Mellitus, Non-Insulin-Dependent, G-Protein-Coupled Receptors, Gastric Inhibitory Polypeptide, Glucagon Receptor, Glucagon-Like Peptide 1, Nordisk, Obesity, oral drugs, Septerna, small molecule therapies

Novo Nordisk; Septerna; GPCR; oral drugs; obesity; type 2 diabetes; cardiometabolic diseases; GLP-1; GIP; glucagon receptors; small molecule therapies; collaboration; pharmaceuticals

Pharma’s wins and losses in Trump’s sprawling executive order on drug prices

2 months ago talkbio0Tagged drug price, Industry, Insulin, IRA, losses, Mediation, Medicare, Prices, small molecule drugs

Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices

Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme

2 months ago talkbio0Tagged Cell Therapy, Clinical Trials, Failure (biologic function), implantable device, Insulin, production, VX-264, zimislecel

Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production

Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks

3 months ago talkbio0Tagged Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Nordisk, Obesity, triple agonist, UBT251, United Laboratories International Holdings Limited

Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited

Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset

3 months ago talkbio0Tagged Bioscience, hydrocortisone, Vision

Vision, hydrocortisone, Bioscience

AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog

3 months ago talkbio0Tagged AbbVie, Amylin Analog, GUB014295, GUBamy, Gubra, Obesity, pharmaceutical licensing, Weight-Loss Agents

AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal

Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate

4 months ago talkbio0Tagged ASC30, Ascletis, Clinical Trials, CT-996, Obesity, Oral cavity, Pharma, Pharmaceutical competition, Product containing glucagon-like peptide 1 receptor agonist (product), Roche (company)

Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

4 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models